Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Background: During the past years biologic agents (also termed biologicals or biologics)
have become a crucial treatment option in immunological diseases. Numerous articles have …

Objective We provide evidence‐based recommendations regarding the treatment of
interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …

Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …

Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical
practice. Methods We performed a prospective study including patients with SSc from the …

Objectives To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with
systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research …

Interstitial lung disease (ILD) encompasses a large and diverse group of pathological
conditions that share similar clinical, radiological and pathological manifestations, despite …

Objectives Rituximab (RTX) may favorably affect lung function and skin fibrosis in patients
with systemic sclerosis (SSc). We aimed to assess long-term efficacy and safety of RTX in …

Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterised by
endothelial dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with …